Caplin Point Labs News and Updates

Name: Latest research reports of Caplin Point Laboratories Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Caplin Point Laboratories Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news on Caplin Point Labs from all sources in a single place.

Caplin Point Laboratories Ltd.

01 Jan 2026

1816.90

-0.11%

Caplin Point strengthens US injectables, opthalmic segment with acquisition of 10 new ANDAs

Business Line

The addressable market of these products was $473.2 million for the 12-month period ending August 2025, the company said in its note to the exchanges

Caplin Point Laborat.. has an average target of 2397.00 from 2 brokers.

Caplin Point Laboratories Ltd.

10 Nov 2025

1816.90

-0.11%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Firm expansion plans in place- In the US, the company is optically transitioning to B2C model to focus on high margin products. The company is also looking for third party ANDAs (4 already acquired, 5 more to come) as well as outsourcing some in-house products to the CMOs for optimal plant utilisation. This, we believe is a part of larger strategy where the company wants to increase the offerings via front-end and at the same time focusing on margin expansion. The legacy LatAm growth was slower seemingly on account of some saturation in the existing markets and focus...

Caplin Point Laborat.. has an average target of 2397.00 from 2 brokers.

Caplin Point Laboratories Ltd.

05 Nov 2025

1816.90

-0.11%

to see Rapid results content

Caplin Point Laboratories Ltd.

03 Sep 2025

1816.90

-0.11%

Caplin Point's unit gets USFDA nod for generic milrinone lactate injection

Business Standard

Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent...

Caplin Point Laboratories Ltd. is trading below all available SMAs

Caplin Point Laboratories Ltd.

22 Aug 2025

1816.90

-0.11%

Stock Market Live Updates 22 August 2025: Stock to buy today: Caplin Point Laboratories

Business Line

Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Caplin Point Laboratories. The 4 per cent rise has taken the share price well above the 2,130-2,140 resistance zone. This region will now act as a good support and limit the downside. Below this 2,080 will be the next important support. Immediate resistance is at 2,230 which can be broken in the next few days. Such a break can take Caplin Point Laboratories share price up to 2,330 in the coming weeks. Traders can buy Caplin Point Laboratories now at 2,205. Accumulate on dips at 2,160. Keep the stop-loss at 2,110 initially. Trail the stop-loss up to 2,225 as soon as the stock goes up to 2,255. Move the stop-loss further up to 2,260 and 2,285 when the price touches 2,280 and 2,300 respectively. Exit the long positions at 2,320.